Skip to main content

and
  1. Article

    Open Access

    Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model

    CDK4/6 inhibitors such as ribociclib are becoming widely used targeted therapies in hormone-receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) breast cancer. However, cancers can...

    Vince Kornél Grolmusz, **feng Chen, Rena Emond in Cancer Cell International (2020)